Teleflex Inc.

TFX

NYSE; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0000096943

D

fourth fifth of 369 graded peers in healthcare

rank 277 of 369; percentile 75.0; sampling error 2.5 points; lower is stronger

A B C D E

D, the sloth



Scoreboard	
Profitability	C percentile 49.7
Solvency	C/D percentile 60.9
Growth and financing	C/D percentile 60.3
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $6.9B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	10 of 14
Graded from	filings received through Feb 27, 2026 258 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$156.22 2026-11-11; market equity $6.2B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 27, 2026

Teleflex Incorporated is referred to herein as "we," "us," "our," "Teleflex" and the "Company." Teleflex is a global provider of medical technology products that enhance clinical benefits, improve patient and provider safety and reduce total procedural costs. We primarily design, develop, manufacture and supply single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. We market and sell our products to hospitals and healthcare providers worldwide through a combination of our direct sales force and distributors.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 49.7						
Gross profitability	16.1%	32.3%		69.8	365	2025-12-31
Return on invested capital	not computable	9.3%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(14.3%)	(6.6%)	31.6	801	2025-12-31
Gross margin stability, five years	2.7 pts	2.8 pts	47.7	242	2025-12-31
Solvency, sleeve percentile 60.9					
Twelve-month failure probability	not computable	0.08%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	3.56	(0.35)	23.3	745	2025-12-31
Net debt to EBITDA	12.97x	1.82x	97.3	75	2025-12-31
Interest coverage	not computable	(4.51x)			
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31					
Current ratio	2.54x	2.95x	62.1	827	2025-12-31
Growth and financing, sleeve percentile 60.3					
Revenue growth, three-year compound	(10.6%)	10.1%	85.6	412	2025-12-31
Free cash flow growth, three-year compound	(82.4%)	11.0%	100.0	95	2025-12-31
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	0.09%	2.2%	51.6	695	2025-12-31
Net share issuance, one year	(4.7%)	2.5%	4.1	628	2026-02-25

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
272	Retractable Technologies Inc. (RVP)	73.6	D	fortress balance sheet
273	Precision Optics Corporation, Inc. (POCI)	73.9	D	dilution, fortress balance sheet
274	NutriBand Inc. (NTRB)	74.2	D	fortress balance sheet
275	Ovid Therapeutics Inc. (OVID)	74.5	D	dilution, short runway
276	Abeona Therapeutics Inc. (ABEO)	74.7	D	fortress balance sheet
277	Teleflex Inc. (TFX)	75.0	D	
278	Standard Biotools Inc. (LAB)	75.3	D	late filer, fortress balance sheet
279	X4 Pharmaceuticals, Inc. (XFOR)	75.5	D	dilution, fortress balance sheet
280	Vir Biotechnology, Inc. (VIR)	75.8	D	
281	Cytosorbents Corp. (CTSO)	76.1	D	short runway, fortress balance sheet
282	Tilray Brands, Inc. (TLRY)	76.4	D	fortress balance sheet

What the price implies

at the 2026-11-11 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	1.6%	(1.9%)	53
Distance from 52-week high	0.0%	(27.8%)	94
EBIT to enterprise value	1.6%	(1.6%)	60
Free cash flow yield	0.02%	(1.0%)	55
Book value to price	0.56	0.27	73
Sales to price	0.32	0.29	52

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Composite equity issuance, five years	(20.3%)	20.8%	9
Relative strength against the sector, log excess return	(0.15)	(0.19)	53

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 5 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$430.5M
Operating cash flow, four quarters	$321.2M
Months of runway	not finite
Days since last periodic filing	7 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$95.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$1.1B	2025-12-31	2026-02-27	10-K	26-000019
2	assets	us-gaap:Assets	$6.9B	2025-12-31	2026-02-27	10-K	26-000019
3	operating income	us-gaap:OperatingIncomeLoss	$118.4M	2025-12-31	2026-02-27	10-K	26-000019
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$24.6M	2025-12-31	2026-02-27	10-K	26-000019
5	income tax	us-gaap:IncomeTaxExpenseBenefit	-$34.0M	2025-12-31	2026-02-27	10-K	26-000019
6	total debt	us-gaap:LongTermDebt	$2.6B	2025-12-31	2026-02-27	10-K	26-000019
7	book equity	us-gaap:StockholdersEquity	$3.1B	2025-12-31	2026-02-27	10-K	26-000019
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$378.6M	2025-12-31	2026-02-27	10-K	26-000019
9	total debt	us-gaap:LongTermDebt	$1.7B	2024-12-31	2026-02-27	10-K	26-000019
10	book equity	us-gaap:StockholdersEquity	$4.3B	2024-12-31	2026-02-27	10-K	26-000019
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$247.9M	2024-12-31	2026-02-27	10-K	26-000019
12	net income	us-gaap:NetIncomeLoss	-$905.6M	2025-12-31	2026-02-27	10-K	26-000019
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivitiesC...	$96.7M	2025-12-31	2026-02-27	10-K	26-000019
14	assets	us-gaap:Assets	$7.1B	2024-12-31	2026-02-27	10-K	26-000019
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.0B	2025-12-31	2026-02-27	10-K	26-000019
16	gross profit	us-gaap:GrossProfit	$1.0B	2024-12-31	2026-02-27	10-K	26-000019
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.7B	2024-12-31	2026-02-27	10-K	26-000019
18	gross profit	us-gaap:GrossProfit	$1.0B	2023-12-31	2026-02-27	10-K	26-000019
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.7B	2023-12-31	2026-02-27	10-K	26-000019
20	gross profit	us-gaap:GrossProfit	$1.5B	2022-12-31	2025-02-28	10-K	25-000031
21	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.8B	2022-12-31	2025-02-28	10-K	25-000031
22	gross profit	us-gaap:GrossProfit	$1.5B	2021-12-31	2024-02-23	10-K	24-000036
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.8B	2021-12-31	2024-02-23	10-K	24-000036
24	current assets	us-gaap:AssetsCurrent	$1.9B	2025-12-31	2026-02-27	10-K	26-000019
25	current liabilities	us-gaap:LiabilitiesCurrent	$762.0M	2025-12-31	2026-02-27	10-K	26-000019
26	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$3.1B	2025-12-31	2026-02-27	10-K	26-000019
27	liabilities	us-gaap:Liabilities	$3.8B	2025-12-31	2026-02-27	10-K	26-000019
28	depreciation amortization	us-gaap:Depreciation	$56.1M	2025-12-31	2026-02-27	10-K	26-000019
29	operating income	us-gaap:OperatingIncomeLoss	$258.7M	2023-12-31	2026-02-27	10-K	26-000019

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

30	interest expense	us-gaap:InterestExpense	$85.1M	2023-12-31	2024-02-23	10-K	24-000036
31	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$95.2M	2025-12-31	2026-02-27	10-K	26-000019
32	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivitiesC...	$301.9M	2024-12-31	2026-02-27	10-K	26-000019
33	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$90.4M	2024-12-31	2026-02-27	10-K	26-000019
34	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivitiesC...	$206.1M	2023-12-31	2026-02-27	10-K	26-000019
35	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$46.4M	2023-12-31	2026-02-27	10-K	26-000019
36	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivitiesC...	$342.8M	2022-12-31	2025-02-28	10-K	25-000031
37	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$79.2M	2022-12-31	2025-02-28	10-K	25-000031
38	current assets	us-gaap:AssetsCurrent	$1.5B	2024-12-31	2026-02-27	10-K	26-000019
39	current liabilities	us-gaap:LiabilitiesCurrent	$649.4M	2024-12-31	2026-02-27	10-K	26-000019
40	assets	us-gaap:Assets	$7.5B	2023-12-31	2025-02-28	10-K	25-000031
41	assets	us-gaap:Assets	$6.9B	2022-12-31	2024-02-23	10-K	24-000036
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	44,200,562	2026-02-25	2026-02-27	10-K	26-000019
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	46,366,463	2025-02-25	2025-02-28	10-K	25-000031

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.